Kenneth S. Thress

7.8k total citations · 7 hit papers
48 papers, 5.7k citations indexed

About

Kenneth S. Thress is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kenneth S. Thress has authored 48 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Kenneth S. Thress's work include Lung Cancer Treatments and Mutations (28 papers), Colorectal Cancer Treatments and Studies (16 papers) and Cancer Genomics and Diagnostics (16 papers). Kenneth S. Thress is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Colorectal Cancer Treatments and Studies (16 papers) and Cancer Genomics and Diagnostics (16 papers). Kenneth S. Thress collaborates with scholars based in United States, United Kingdom and Taiwan. Kenneth S. Thress's co-authors include Pasi A. Jänne, J. Carl Barrett, Mireille Cantarini, Geoffrey R. Oxnard, Cloud P. Paweletz, James Chih‐Hsin Yang, Daniel Stetson, Zhongwu Lai, Joanna Roberts and Mark Groudine and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Kenneth S. Thress

48 papers receiving 5.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Kenneth S. Thress, Cloud P. Paweletz et al. Nature Medicine profile →
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

2016 641 citations Geoffrey R. Oxnard, Kenneth S. Thress et al. Journal of Clinical Oncology profile →
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

2016 523 citations Peter Ballard, James Yates et al. Clinical Cancer Research profile →
Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

2018 513 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. profile →
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

2015 401 citations Kenneth S. Thress, Roz Brant et al. Lung Cancer profile →
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

2017 380 citations Suresh S. Ramalingam, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Geoffrey R. Oxnard, J.C.-H. Yang et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Kenneth S. Thress

Since Specialization

Citations

This map shows the geographic impact of Kenneth S. Thress's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth S. Thress with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth S. Thress more than expected).

Fields of papers citing papers by Kenneth S. Thress

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth S. Thress. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth S. Thress. The network helps show where Kenneth S. Thress may publish in the future.

Co-authorship network of co-authors of Kenneth S. Thress

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth S. Thress. A scholar is included among the top collaborators of Kenneth S. Thress based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth S. Thress. Kenneth S. Thress is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Alexander G. Raufi, Lipika Goyal, Elizabeth Smyth, Philip Szekeres, Marcella Petrone, (unknown), Kenneth S. Thress, (unknown), (unknown), (unknown), Rakesh Kumar, (unknown), Laura Barker, Yelena Y. Janjigian, Kohei Shitara	3
2	CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma. 2024 ·Journal of Clinical Oncology ·(unknown), Sophie E. Willis, (unknown), (unknown), (unknown), (unknown), Chris G. Richardson, Andrew G. Chambers, Yeoun Jin Kim, Tsu‐Shuen Tsao, Mark D. Robida, Jan Maciej Zaucha, Deborah L. Berry, Gemma N. Jones, Allison Barrett, Nicholas M. Durham, Marlon C. Rebelatto, Maria A.S. Broggi, Kenneth S. Thress, Nicolás A. Giraldo	1
3	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers 2021 ·Nature Communications ·Tereza Vaclová, Ursula Grazini, Lewis S. C. Ward, Daniel O’Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan J. Hartmaier, Kenneth S. Thress, Paul D. Smith, J. Carl Barrett, Julian Downward, Elza C. de Bruin	46
4	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer breakdown → 2020 ·Annals of Oncology ·Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu, Seung‐Whan Kim, Hideo Saka, Leora Horn, Kōichi Goto, Yuichiro Ohe, Helen Mann, Kenneth S. Thress, Melanie M. Frigault, Karthick Vishwanathan, Dana Ghiorghiu, Suresh S. Ramalingam, Myung‐Ju Ahn	303
5	Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·Chia‐Chi Hsu, Bin-Chi Liao, Wei‐Yu Liao, Aleksandra Markovets, Daniel Stetson, Kenneth S. Thress, James Chih‐Hsin Yang	61
6	Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis. 2019 ·Journal of Clinical Oncology ·Mansoor Raza Mirza, Bin Feng, Ming Shan, Kaiming Sun, (unknown), Kevin Coleman, Kenneth S. Thress, Sebastien Hazard, (unknown), Ursula A. Matulonis	2
7	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib 2017 ·Journal of Thoracic Oncology ·Suzanne Jenkins, James Chih‐Hsin Yang, Pasi A. Jänne, Kenneth S. Thress, Karen Yu, Rachel Hodge, Susie Weston, Simon Dearden, S. Patel, Mireille Cantarini, Frances A. Shepherd	46
8	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial 2017 ·Journal of Thoracic Oncology ·Kenneth S. Thress, Vivien N. Jacobs, Helen K. Angell, James Chih‐Hsin Yang, Lecia V. Sequist, Fiona Blackhall, Wu‐Chou Su, Martin Schüler, Jürgen Wolf, Kathryn A. Gold, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne	17
9	A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report 2017 ·Cellular Oncology ·Suning Chen, Stefan Nagel, Björn Schneider, Haiping Dai, Robert Geffers, Maren Kaufmann, Corinna Meyer, Claudia Pommerenke, Kenneth S. Thress, Jiao Li, Hilmar Quentmeier, Hans G. Drexler, Roderick A.F. MacLeod	18
10	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity breakdown → 2016 ·Clinical Cancer Research ·Peter Ballard, James Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, (unknown), Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren A.E. Cross	523
11	A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next-Generation Sequencing Assay 2016 ·Journal of Thoracic Oncology ·Roopika Menon, (unknown), (unknown), Sotirios Lakis, Kenneth S. Thress, Jürgen Wolf, Lukas C. Heukamp, Johannes M. Heuckmann, Frank Griesinger	25
12	135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC 2016 ·Journal of Thoracic Oncology ·Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden, Rachael Lawrance, Cloud P. Paweletz, Mireille Cantarini, Carl Barrett, James Chih‐Hsin Yang, Pasi A. Jänne	11
13	Design, execution, and preliminary biomarker results from paired tumor biopsy cohorts of the AZD9291 AURA trial 2015 ·Journal of Thoracic Oncology ·Kenneth S. Thress, (unknown), Joseph Geradts, Martin Schüler, Myung‐Ju Ahn, Juergen Wolf, Kathryn A. Gold, James Chih‐Hsin Yang, Fiona Blackhall, Wu‐Chou Su, Vivien N. Jacobs, Neil R. Smith, Helen K. Angell, Kathryn Brown, (unknown), J. Carl Barrett, Mireille Cantarini, (unknown)	1
14	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 2015 ·European Journal of Cancer ·Ian W. Flinn, Nancy L. Bartlett, Kristie A. Blum, Kirit M. Ardeshna, Ann S. LaCasce, Christopher R. Flowers, Andrei R. Shustov, Kenneth S. Thress, Pat Mitchell, (unknown), Jeffrey Skolnik, Jonathan W. Friedberg	61
15	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M breakdown → 2015 ·Nature Medicine ·Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, (unknown), Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard	1189
16	EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291 breakdown → 2015 ·Lung Cancer ·Kenneth S. Thress, Roz Brant, T. Hedley Carr, Simon Dearden, Suzanne Jenkins, Helen Brown, Tracey Hammett, Mireille Cantarini, J. Carl Barrett	401
17	Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System 2014 ·Clinical Cancer Research ·Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett, Chris Harbron, J. Carl Barrett, Elizabeth A. Harrington, Kenneth S. Thress	54
18	AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts 2012 ·Cancer Chemotherapy and Pharmacology ·Radhika Iyer, Carly R. Varela, Jane E. Minturn, Ruth Ho, Anisha M. Simpson, (unknown), Audrey E. Evans, Huaqing Zhao, Kenneth S. Thress, Jeffrey L. Brown, Garrett M. Brodeur	20
19	Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway 2009 ·Molecular Cancer Therapeutics ·Kenneth S. Thress, Terry Macintyre, Haiyun Wang, (unknown), (unknown), Ethan Hoffmann, Tao Wang, Jeffrey L. Brown, Kevin R. Webster, Charles A. Omer, Peter E. Zage, (unknown), Patrick A. Zweidler‐McKay	51
20	Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper 2001 ·The EMBO Journal ·Kenneth S. Thress	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact